

# 2<sup>nd</sup> Annual Symposium on Pancreatic Cancer

Hickey Auditorium – MD Anderson Cancer Center – February 25, 2019

## Morning Session | Chairs: Julie Carstens, Ph.D. and Andrew Rhim, M.D.

8:00 – 8:05 a.m.	<b>Raghu Kalluri, M.D., Ph.D.</b> MD Anderson Cancer Center	Welcome and Opening Remarks
8:05 – 8:20 a.m.	<b>Patient Advocate</b> MD Anderson Cancer Center	Patient Voice
8:20 – 9:15 a.m.	<b>Douglas Hanahan, Ph.D.</b> Swiss Institute for Experimental Cancer Research	<b>Opening Keynote</b> <i>Molecular Mechanisms of Invasion and Metastasis</i>  Introduction by Raghu Kalluri, M.D., Ph.D.
9:15 – 9:45 a.m.	<b>Andrew Aguirre, M.D., Ph.D.</b> Dana-Farber Cancer Institute	<i>Germline and Somatic Mutations in Pancreatic Cancer: Practical Considerations</i>
9:45 – 10:15 a.m.	<b>Diane Simeone, M.D.</b> New York University	<i>Perspectives of a Surgeon Scientist: Approaching Research in Pancreatic Cancer from the Laboratory and the Clinic</i>
10:15 – 10:30 a.m.	<b>BREAK</b>	

## Mid-Morning Session | Chairs: Yejing Ge, Ph.D. and Rosa Hwang, M.D.

10:30 – 11 a.m.	<b>Vinod Balachandran, M.D.</b> Memorial Sloan Kettering Cancer Center	<i>Immunogenic Neoantigens in Pancreatic Cancer: From Discovery to Clinical Application</i>
11 – 11:30 a.m.	<b>Ronald DePinho, M.D.</b> MD Anderson Cancer Center	<i>Targeting Tumor Microenvironment Interactions</i>
11:30 a.m. – Noon	<b>Joseph Herman, M.D.</b> MD Anderson Cancer Center	<i>Pancreas SBRT: Ablation, Prevention, or Potentiation?</i>
Noon – 12:15 p.m.	<b>LUNCH PICK UP</b> <i>Boxed lunches provided in the foyer.</i>	

## Afternoon Session | Chairs: Michael Kim, M.D., and Haoqiang Ying, M.D., Ph.D

12:15 – 1:45 p.m.	<b>OPEN FORUM: <i>Strategies for Effective Treatment of Pancreatic Cancer</i></b> <b>Chairs:</b> Eileen O'Reilly, M.D. and Robert Wolff, M.D. <b>Panel Members:</b> Joseph Herman, M.D., Michael Kim, M.D., Anirban Maitra, M.B.B.S., Florencia McAllister, M.D. and Robert Wolff, M.D.	
1:45 – 1:55 p.m.	<b>BREAK</b>	

(Afternoon session continued on reverse)

### Accreditation/Designation Statement

The University of Texas MD Anderson Cancer Center is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Texas MD Anderson Cancer Center designates this live activity for a maximum of 8.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

# 2<sup>nd</sup> Annual Symposium on Pancreatic Cancer

Hickey Auditorium – MD Anderson Cancer Center – February 25, 2019

## Afternoon Session (cont.) | Chairs: Haoqiang Ying, M.D., Ph.D. and Michael Kim, M.D.

1:55 – 2:25 p.m.	<b>Anil Rustgi, M.D.</b> University of Pennsylvania	<i>Regulation of Plasticity in Metastatic Pancreatic Cancer Organotropism</i>
2:25 – 2:55 p.m.	<b>Robert Wolff, M.D.</b> MD Anderson Cancer Center	<i>Challenges in Clinical Trial Design for Patients with Localized and Locally Advanced Pancreatic Cancer</i>
2:55 – 3:25 p.m.	<b>Eileen O'Reilly, M.D.</b> Memorial Sloan Kettering Cancer Center	<i>Challenges of Clinical Research in Patients with Metastatic Disease</i>
3:25 – 3:35 p.m.	<b>BREAK</b>	
3:35 – 4:05 p.m.	<b>Raghu Kalluri, M.D., Ph.D.</b> MD Anderson Cancer Center	<i>Identification of A Novel Oncogenic Type I Collagen Variant in the Initiation and Progression of Pancreatic Cancer</i>
4:05 – 5 p.m.	<b>James Allison, Ph.D.</b> MD Anderson Cancer Center	<b>Closing Keynote</b> <i>Immune Checkpoint Blockade in Cancer Therapy: New Insights, Opportunities, and Prospects for Cures</i>
		Introduction by Ronald DePinho, M.D.

*Support for our symposium comes in part from the Khalifa Institute for Personalized Cancer Therapy, The Department of Cancer Biology, and Metastasis Research Center.*